Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-01-28 4:00 pm Sale | 2024-12-31 | 13G | Astria Therapeutics, Inc. ATXS | Integrated Core Strategies (US) LLC | 1,994,503 3.500% | -954,373 (-32.36%) | Filing History |
| 2025-01-07 07:45 am Purchase | 2024-12-30 | 13G | Astria Therapeutics, Inc. ATXS | ForGrowth III PA B.V. | 2,872,537 5.100% | 2,872,537 (New Position) | Filing History |
| 2024-11-14 5:46 pm Purchase | 2024-09-30 | 13G | Astria Therapeutics, Inc. ATXS | RA CAPITAL MANAGEMENT L.P. | 5,105,213 9.000% | 692,063 (+15.68%) | Filing History |
| 2024-11-14 5:45 pm Purchase | 2024-09-30 | 13G | Astria Therapeutics, Inc. ATXS | Venrock Healthcare Capital Partners III L.P. | 3,458,645 6.100% | 232,839 (+7.22%) | Filing History |
| 2024-11-14 4:41 pm Unchanged | 2024-11-14 | 13D | Astria Therapeutics, Inc. ATXS | Perceptive Advisors LLC | 6,485,420 11.500% | 0 (Unchanged) | Filing History |
| 2024-11-14 4:15 pm Purchase | 2024-09-30 | 13G | Astria Therapeutics, Inc. ATXS | Fairmount Funds Management LLC | 5,868,045 9.900% | 2,234,080 (+61.48%) | Filing History |
| 2024-11-14 12:03 pm Purchase | 2024-09-30 | 13G | Astria Therapeutics, Inc. ATXS | Vestal Point Capital LP | 4,000,000 7.100% | 4,000,000 (New Position) | Filing History |
| 2024-11-13 4:21 pm Sale | 2024-09-30 | 13G | Astria Therapeutics, Inc. ATXS | TCG Crossover GP II, LLC | 2,761,861 4.900% | -1,607,067 (-36.78%) | Filing History |
| 2024-11-12 1:29 pm Unchanged | 2024-09-30 | 13G | Astria Therapeutics, Inc. ATXS | The Vanguard Group | 2,635,520 4.670% | 0 (Unchanged) | Filing History |
| 2024-11-12 09:50 am Purchase | 2024-11-08 | 13G | Astria Therapeutics, Inc. ATXS | FMR LLC | 8,463,678 14.999% | 1,767,714 (+26.40%) | Filing History |
| 2024-11-08 2:17 pm Unchanged | 2024-09-30 | 13G | Astria Therapeutics, Inc. ATXS | BlackRock Inc. BLK | 3,499,478 6.200% | 0 (Unchanged) | Filing History |
| 2024-11-04 12:37 pm Unchanged | 2024-09-30 | 13G | Astria Therapeutics, Inc. ATXS | The Vanguard Group | 2,635,520 4.670% | 0 (Unchanged) | Filing History |
| 2024-11-04 11:39 am Unchanged | 2024-09-30 | 13G | Astria Therapeutics, Inc. ATXS | The Vanguard Group | 2,635,520 4.670% | 0 (Unchanged) | Filing History |
| 2024-11-04 11:39 am Purchase | 2024-09-30 | 13G | Astria Therapeutics, Inc. ATXS | The Vanguard Group | 2,635,520 4.670% | 579,813 (+28.21%) | Filing History |
| 2024-11-01 4:05 pm Purchase | 2024-10-28 | 13G | Astria Therapeutics, Inc. ATXS | Integrated Core Strategies (US) LLC | 2,948,876 5.200% | 2,948,876 (New Position) | Filing History |
| 2024-10-24 2:02 pm Purchase | 2024-09-30 | 13G | Astria Therapeutics, Inc. ATXS | BlackRock Inc. BLK | 3,499,478 6.200% | 1,043,825 (+42.51%) | Filing History |
| 2024-07-10 10:10 am Purchase | 2024-07-09 | 13G | Astria Therapeutics, Inc. ATXS | FMR LLC | 6,695,964 12.193% | 1,732,228 (+34.90%) | Filing History |
| 2024-03-11 08:19 am Sale | 2024-03-08 | 13G | Astria Therapeutics, Inc. ATXS | FMR LLC | 4,963,736 9.080% | -480,692 (-8.83%) | Filing History |
| 2024-03-07 12:29 pm Purchase | 2024-02-29 | 13G | Astria Therapeutics, Inc. ATXS | BlackRock Inc. BLK | 2,455,653 4.500% | 271,095 (+12.41%) | Filing History |
| 2024-02-14 3:48 pm Purchase | 2023-12-31 | 13G | Astria Therapeutics, Inc. ATXS | Fairmount Funds Management LLC | 3,633,965 9.900% | 1,732,568 (+91.12%) | Filing History |